Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC): A Randomize

Press/Media

Period	21 Jan 2023

Media coverage

Title	Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC): A Randomize
Media name/outlet	MarketScreener.com
Country/Territory	United States
Date	21/01/23
URL	https://www.marketscreener.com/quote/stock/RENOVORX-INC-125706124/news/Targeted-Intra-arterial-Gemcitabine-vs-Continuation-of-IV-Gemcitabine-Plus-Nab-paclitaxel-Following-42780976/
Persons	Karyn Goodman